PIT-565

N/A

Report date: 2026/05/25 20:02:40

Base Information

Drug NamePIT-565
Drug Alias NamePIT-565
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-CD19Anti-CD3Anti-CD2
TargetsB-lymphocyte antigen CD19T-cell surface antigen CD2T cell surface glycoprotein CD3
Therapy Area/IndicationsLupus Erythematosus, SystemicNephrosisArthritis, Rheumatoid +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumBulgariaUnited States +[16] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma AgLonza AGChina Novartis Institutes For Biomedical Research Co Ltd
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, SystemicNephrosisArthritis, Rheumatoid +[5] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A